Jong Bok Lee Selected Research

Graves Ophthalmopathy

8/2014	Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy.
4/2014	Pirfenidone attenuates the IL-1β-induced hyaluronic acid increase in orbital fibroblasts from patients with thyroid-associated ophthalmopathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jong Bok Lee Research Topics

Disease

6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 04/2018
6	Exotropia (Exophoria) 09/2020 - 01/2007
5	Neoplasms (Cancer) 01/2022 - 01/2019
4	Strabismus (Squint) 01/2015 - 09/2005
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 01/2019
2	Lymphoma (Lymphomas) 01/2021 - 01/2019
2	B-Cell Leukemia (Leukemia, B Cell) 01/2021 - 01/2019
2	Lung Neoplasms (Lung Cancer) 03/2019 - 01/2019
2	Leukemia 03/2019 - 04/2018
2	Ganglion Cysts (Ganglion) 08/2017 - 12/2015
2	Optic Nerve Diseases (Optic Neuropathy) 12/2015 - 09/2013
2	Graves Ophthalmopathy 08/2014 - 04/2014
2	Diplopia (Double Vision) 09/2009 - 09/2005
2	Cicatrix (Scar) 12/2008 - 05/2007
1	Bites and Stings (Sting) 01/2021
1	Overactive Urinary Bladder (Overactive Bladder) 11/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2019
1	Cytokine Release Syndrome 01/2019
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019
1	X-Linked Infantile Nystagmus 08/2017
1	Esotropia (Esophoria) 01/2015
1	Craniosynostoses (Craniosynostosis) 01/2015
1	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 09/2013
1	Astigmatism 05/2011
1	Coma (Comas) 05/2011
1	Cataract (Cataracts) 09/2009
1	Amblyopia (Lazy Eye) 12/2008
1	Ischemia 01/2007
1	Rupture 01/2007
1	Atherosclerosis 06/2004
1	Acute Coronary Syndrome 06/2004
1	Coronary Artery Disease (Coronary Atherosclerosis) 06/2004
1	Myocardial Infarction 06/2004

Drug/Important Bio-Agent (IBA)

4	2,6-dinitrotoluene (DNT)IBA 03/2019 - 04/2018
3	Chimeric Antigen ReceptorsIBA 01/2022 - 01/2019
2	AntigensIBA 01/2022 - 01/2019
2	Retinaldehyde (Retinal)IBA 08/2017 - 12/2015
2	Type A Botulinum Toxins (Botox)FDA Link 02/2012 - 01/2007
1	idelalisibIBA 10/2021
1	venetoclaxIBA 01/2021
1	Azacitidine (5 Azacytidine)FDA Link 01/2021
1	Muscarinic AntagonistsIBA 11/2020
1	NivolumabIBA 03/2019
1	Immune Checkpoint InhibitorsIBA 03/2019
1	LigandsIBA 01/2019
1	Interleukin-15 (Interleukin 15)IBA 01/2019
1	Ethambutol (Myambutol)FDA LinkGeneric 12/2015
1	AntioxidantsIBA 08/2014
1	Therapeutic UsesIBA 08/2014
1	tanshinoneIBA 08/2014
1	Hyaluronic Acid (Hyaluronan)IBA 04/2014
1	Troleandomycin (TAO)FDA Link 04/2014
1	pirfenidoneIBA 04/2014
1	Linezolid (Zyvox)FDA Link 09/2013
1	1-amino-3-imino-N,N'-propene diacetateIBA 01/2012
1	4-hexyloxyaniline (HOA)IBA 05/2011
1	Anesthetics (Anesthetic Agents)IBA 09/2009
1	Protein Glutamine gamma Glutamyltransferase 2IBA 05/2007
1	Platelet Membrane GlycoproteinsIBA 06/2004
1	Glycoproteins (Glycoprotein)IBA 06/2004
1	Integrin alpha2IBA 06/2004

Therapy/Procedure

10	Therapeutics 01/2022 - 12/2008
3	Sutures (Suture) 09/2020 - 09/2005
2	Hematopoietic Stem Cell Transplantation 01/2022 - 01/2019
2	Immunotherapy 01/2019 - 01/2019
2	Nerve Block (Nerve Blocks) 02/2012 - 01/2007
2	Anesthesia 03/2011 - 09/2009
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2019
1	Aftercare (After-Treatment) 01/2019
1	Drug Therapy (Chemotherapy) 04/2018
1	Distraction Osteogenesis 01/2015
1	Orthoptics (Orthoptic) 01/2015
1	General Anesthesia 01/2012
1	Eyeglasses (Spectacles) 09/2011
1	Filtering Surgery 05/2007
1	Telescopes 09/2005